Extended Data Fig. 3: CD70 deficiency does not impair cDC1 development.

a, Percentages of splenic cDCs (left) and T and B cells (right) between WT (Xcr1^+/+ Cd70^fl/fl, black circles) and Cd70^cKO (Xcr1^Cre/+ Cd70^fl/fl, orange circles) mice at homeostasis. b, Representative flow plots depicting CD70 expression in cDC1 (left) and cDC2 (right) from Flt3L-treated BM cultures of WT (top) and Cd70^cKO (bottom) stimulated with αCD40 + poly(I:C). c, Representative flow plots showing CD70 and CD40 expression in migratory cDC1s of naive SDLN (left) and day 6 TDLNs (1969 fibrosarcoma, top; 1956-mOVA, bottom) of WT (Xcr1^+/+ Cd40^fl/fl) and Cd40^cKO (Xcr1^+/+ Cd40^fl/fl) mice. d, Proliferation of CTV-labeled OT-I CD8 T cells adoptively transferred into WT (Xcr1^+/+ Cd70^fl/fl, black circles) or Cd70^cKO (orange circles) mice was analyzed 72 h after immunization with OVA-loaded splenocytes. Data represent pooled biologically independent samples from two independent experiments (n = 4 for WT and Cd70^cKO –OVA splenocytes, n = 5-6 for WT and Cd70^cKO + OVA splenocytes). Data represented as mean +/− s.d. e, Cd40^WT (Xcr1^+/+ Cd40^fl/fl), Cd40^cKO, Cd70^WT (Xcr1^+/+ Cd70^fl/fl), and Cd70^cKO mice were injected with 10⁶ 1969 cells, and spleens were stained for the presence of mGpd2 tetramer⁺ CD8 T cells on day 10. Data represent pooled biologically independent samples from three independent experiments (n = 3 for naive, n = 5 for Cd40^WT, n = 5 for Cd40^cKO, n = 6 for Cd70^WT, and n = 5 for Cd70^cKO mice). f, Individual tumor curves of WT (Xcr1^+/+ Cd70^fl/fl), Cd40^cKO, and Cd70^cKO mice during primary and secondary implantation with 1956 progressor tumor. d: Brown–Forsythe and Welch ANOVA with Dunnett’s T3 multiple comparisons test.

Source data